101 related articles for article (PubMed ID: 28818952)
1. Enasidenib Approved for AML, but Best Uses Unclear.
Cancer Discov; 2017 Oct; 7(10):OF4. PubMed ID: 28818952
[TBL] [Abstract][Full Text] [Related]
2. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia.
Abou Dalle I; DiNardo CD
Ther Adv Hematol; 2018 Jul; 9(7):163-173. PubMed ID: 30013764
[TBL] [Abstract][Full Text] [Related]
3. Enasidenib: An Oral IDH2 Inhibitor for the Treatment of Acute Myeloid Leukemia.
Myers RA; Wirth S; Williams S; Kiel PJ
J Adv Pract Oncol; 2018; 9(4):435-440. PubMed ID: 30719396
[TBL] [Abstract][Full Text] [Related]
4. Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy.
Galkin M; Jonas BA
Core Evid; 2019; 14():3-17. PubMed ID: 31118877
[No Abstract] [Full Text] [Related]
5. Thyroiditis: A Rare Manifestation of Enasidenib-Induced Differentiation Syndrome.
Annamaraju P; Gopishetty S; Goparaju N; Beasey M; Kota V; Guddati AK
Case Rep Oncol; 2020; 13(2):583-587. PubMed ID: 32547385
[TBL] [Abstract][Full Text] [Related]
6. Enasidenib in acute myeloid leukemia: clinical development and perspectives on treatment.
Reed DR; Elsarrag RZ; Morris AL; Keng MK
Cancer Manag Res; 2019; 11():8073-8080. PubMed ID: 31564968
[TBL] [Abstract][Full Text] [Related]
7. Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML.
Jasra S; Kazemi M; Shah N; Chen J; Fehn K; Wang Y; Mantzaris I; Kornblum N; Sica A; Bachier L; Goldfinger M; Gritsman K; Braunschweig I; Steidl U; Shastri A; Verma A
Exp Hematol Oncol; 2021 Jan; 10(1):1. PubMed ID: 33397455
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
9. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Short NJ; Ravandi F
Expert Rev Hematol; 2016 Jun; 9(6):529-34. PubMed ID: 27158854
[TBL] [Abstract][Full Text] [Related]
10. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?
Samuel AM; Rathi VK; Grauer JN; Ross JS
Clin Orthop Relat Res; 2016 Apr; 474(4):1053-68. PubMed ID: 26584802
[TBL] [Abstract][Full Text] [Related]
11. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
Azebu LM
Food Drug Law J; 2014; 69(1):87-111, ii-iii. PubMed ID: 24772687
[TBL] [Abstract][Full Text] [Related]
12. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
[TBL] [Abstract][Full Text] [Related]
13. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
14. Antibody therapy for acute myeloid leukemia.
Mulford D
Semin Hematol; 2008 Apr; 45(2):104-9. PubMed ID: 18381105
[TBL] [Abstract][Full Text] [Related]
15. Technology evaluation: gemtuzumab ozogamicin, Celltech Group.
Niculescu-Duvaz I
Curr Opin Mol Ther; 2000 Dec; 2(6):691-6. PubMed ID: 11249747
[TBL] [Abstract][Full Text] [Related]
16. Physicians' Trust in the FDA's Use of Product-Specific Pathways for Generic Drug Approval.
Kesselheim AS; Eddings W; Raj T; Campbell EG; Franklin JM; Ross KM; Fulchino LA; Avorn J; Gagne JJ
PLoS One; 2016; 11(10):e0163339. PubMed ID: 27768700
[TBL] [Abstract][Full Text] [Related]
17. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
18. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015.
Gopal AD; Rathi VK; Teng CC; Del Priore L; Ross JS
Ophthalmology; 2017 Aug; 124(8):1237-1246. PubMed ID: 28501378
[TBL] [Abstract][Full Text] [Related]
19. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
Basile EM; Tolomeo D; Gluck E
Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
[TBL] [Abstract][Full Text] [Related]
20. Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies.
Carella AM; Berman E; Maraone MP; Ganzina F
Haematologica; 1990; 75(2):159-69. PubMed ID: 2192943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
